Article

Galectin antagonist use in mild cases of SARS-CoV-2; pilot feasibility randomised, open label, controlled trial

2020-12-04

Abstract excerpt

<h4>Importance</h4> Novel SARS-CoV-2 virus has infected nearly half a billion people across the world and is highly contagious. There is a need for a novel mechanism to block viral entry and stop its replication. <h4>Background</h4> Spike protein N terminal domain (NTD) of the novel SARS-CoV-2 is essential for viral entry and replication in human cell. Thus the S1 NTD of human coronavirus family, which is similar...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d37cd7b5-bc7a-5e7c-bc19-6a9647a35333
DOI: 10.1101/2020.12.03.20238840

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Galectin antagonist use in mild cases of SARS-CoV-2; pilot feasibility randomised, open label, controlled trialDOI 10.1101/2020.12.03.20238840Read

Galectin approach to lower covid transmission - Drug Development for clinical useSemantic proximity Read

The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trialSemantic proximity Read

Minimal impact of ivermectin on immune response and transcriptional profiles in naïve adults with mild COVID-19Semantic proximity Read

Pharmacometric assessment of the <i>in vivo</i> antiviral activity of ivermectin in early symptomatic COVID-19Semantic proximity Read

THE THERAPEUTIC POTENTIAL OF IVERMECTIN FOR COVID-19: A SYSTEMATIC REVIEW OF MECHANISMS AND EVIDENCESemantic proximity Read

Understanding the role of galectin inhibitors as potential candidates for SARS-CoV-2 spike protein: in silico studiesSemantic proximity Read

Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replicationSemantic proximity Read

Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical TrialSemantic proximity Read

THE THERAPEUTIC POTENTIAL OF IVERMECTIN FOR COVID-19: A SYSTEMATIC REVIEW OF MECHANISMS AND EVIDENCESemantic proximity Read

Research Into Potential Therapies Against COVID-19, With Focus On IvermectinSemantic proximity Read

Research Into Potential Therapies Against COVID-19, With Focus On IvermectinSemantic proximity Read

SARS-COV-2 nasopharyngeal viral load change in a multicenter randomized clinical trial comparing early therapies for COVID-19 in non-hospitalized adults with high risk of severe COVID-19 (the MONET TRIAL)Semantic proximity Read